论文部分内容阅读
目的探讨孟鲁司特联合沙丁胺醇气雾剂治疗咳嗽变异性哮喘的疗效及对炎症因子的影响。方法选取2015年1月—2016年1月渭南市妇幼保健院儿科收治的咳嗽变异性哮喘患者120例,随机平均分配为观察组和对照组,对照组仅给予沙丁胺醇气雾剂治疗,观察组给予孟鲁司特联合沙丁胺醇气雾剂治疗。比较两组患者的临床疗效、患者肺功能恢复情况以及血清中炎症因子变化情况。结果治疗2个月后,对照组和观察组的有效率分别为73.3%和96.7%,观察组的有效率明显高于对照组,两组比较差异显著(P<0.05)。治疗前,两组患者FEV1、FEV1/FVC等肺功能相关的指标无统计学差异。治疗后,两组患者FEV1、FEV1/FVC均显著升高,与治疗前比较差异显著(P<0.05);且观察组明显高于对照组,两组比较差异显著(P<0.05)。治疗前,两组患者血清IL-6、TNF-α水平无显著差异;治疗后,两组患者IL-6、TNF-α水平均显著降低,与治疗前比较差异显著(P<0.05);且观察组患者治疗血清IL-6、TNF-α水平显著低于对照组(P<0.05)。结论采用孟鲁司特联合沙丁胺醇气雾剂治疗咳嗽变异性哮喘安全有效,可显著改善患者肺功能并降低炎症因子水平。
Objective To investigate the effect of montelukast combined with salbutamol aerosol on cough variant asthma and its effect on inflammatory factors. Methods 120 patients with cough variant asthma admitted to Weinan MCH from January 2015 to January 2016 were randomly divided into observation group and control group. The control group was treated with albuterol only. The observation group was given Montelukast combined with salbutamol aerosol therapy. The clinical efficacy, the recovery of lung function and the changes of inflammatory cytokines in the two groups were compared. Results After 2 months of treatment, the effective rates of the control group and the observation group were 73.3% and 96.7%, respectively. The effective rate of the observation group was significantly higher than that of the control group (P <0.05). Before treatment, pulmonary function FEV1, FEV1 / FVC and other indicators of the two groups were not statistically different. After treatment, FEV1 and FEV1 / FVC in both groups were significantly increased (P <0.05), and the observation group was significantly higher than the control group, the difference was significant (P <0.05). Before treatment, there was no significant difference in serum IL-6 and TNF-α levels between the two groups. After treatment, the levels of IL-6 and TNF-α in both groups were significantly lower than those before treatment (P <0.05); and The levels of IL-6 and TNF-α in the observation group were significantly lower than those in the control group (P <0.05). Conclusion Montelukast combined with salbutamol aerosol treatment of cough variant asthma is safe and effective, can significantly improve lung function and reduce the level of inflammatory cytokines.